Literature DB >> 7855342

Diffuse disease of the liver: radiologic-pathologic correlation.

P J Mergo1, P R Ros, P C Buetow, J L Buck.   

Abstract

Cross-sectional imaging is playing an increasing role in diagnosis of diffuse liver diseases because it clarifies, in many cases, the overlap in clinical and laboratory manifestations often present in diffuse hepatic processes and thus may eliminate the need for a biopsy. Advances in cross-sectional imaging, particularly in magnetic resonance (MR) imaging, enable further characterization of hepatic parenchymal and architectural changes, allowing closer correlation with underlying pathologic changes. Advanced imaging techniques can be used to characterize a variety of metabolic, vascular, toxic, infectious, and neoplastic diffuse liver diseases. These include more common entities such as cirrhosis, Budd-Chiari syndrome, hemochromatosis, Wilson disease, fatty change, and diffuse neoplastic disease (hepatocellular carcinoma, metastasis, and lymphoma) and uncommon entities such as schistosomiasis, sarcoidosis, and amyloidosis. Correlation of computed tomographic and MR imaging findings with underlying pathologic features is helpful in understanding the gamut of diffuse diseases of the liver.

Entities:  

Mesh:

Year:  1994        PMID: 7855342     DOI: 10.1148/radiographics.14.6.7855342

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  11 in total

1.  Harmonization of radiomic feature distributions: impact on classification of hepatic tissue in CT imaging.

Authors:  Hubert Beaumont; Antoine Iannessi; Anne-Sophie Bertrand; Jean Michel Cucchi; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2021-01-18       Impact factor: 5.315

2.  Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C.

Authors:  A K P Lim; S D Taylor-Robinson; N Patel; R J Eckersley; R D Goldin; G Hamilton; G R Foster; H C Thomas; D O Cosgrove; M J K Blomley
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

3.  Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study.

Authors:  M J K Blomley; A K P Lim; C J Harvey; N Patel; R J Eckersley; R Basilico; R Heckemann; A Urbank; D O Cosgrove; S D Taylor-Robinson
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

4.  Imaging findings of upper abdominal involvement by acute megakaryoblastic leukaemia.

Authors:  Shiori Amemiya; Masaaki Akahane; Junko Takita; Takashi Igarashi; Kuni Ohtomo
Journal:  Pediatr Radiol       Date:  2008-01-03

Review 5.  Other types of diffuse liver disease: is there a way to do it?

Authors:  Hilton Leao Filho; Camila Vilela de Oliveira; Natally Horvat
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 6.  Imaging of multifocal hepatic lesions in pediatric patients.

Authors:  Shauna Duigenan; Sudha A Anupindi; Katherine Nimkin
Journal:  Pediatr Radiol       Date:  2012-05-08

7.  Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis.

Authors:  Luke Hahn; Scott B Reeder; Alejandro Muñoz del Rio; Perry J Pickhardt
Journal:  AJR Am J Roentgenol       Date:  2015-12       Impact factor: 3.959

8.  Clinical application of liver MR imaging in Wilson's disease.

Authors:  Jung-Eun Cheon; In-One Kim; Jeong Kee Seo; Jae Sung Ko; Jeong Min Lee; Cheong-Il Shin; Woo Sun Kim; Kyung Mo Yeon
Journal:  Korean J Radiol       Date:  2010-10-29       Impact factor: 3.500

9.  MDCT Imaging Findings of Liver Cirrhosis: Spectrum of Hepatic and Extrahepatic Abdominal Complications.

Authors:  Guillermo P Sangster; Carlos H Previgliano; Mathieu Nader; Elisa Chwoschtschinsky; Maureen G Heldmann
Journal:  HPB Surg       Date:  2013-08-06

10.  Bile Duct Strictures Caused by Solid Masses: MR in Differential Diagnosis and as a Prognostic Tool to Plan the Endoscopic Treatment.

Authors:  Tomasz Gorycki; Michał Studniarek
Journal:  Gastroenterol Res Pract       Date:  2013-11-05       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.